bioAffinity Technologies, Inc. — Regulatory Filings 2025

Sep 9, 2025

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2025

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-41463	46-5211056
(State
or other jurisdiction of
incorporation)	(Commission File
Number)	(I.R.S.
Employer Identification
Number)

3300 Nacogdoches Road , Suite 216

San Antonio , Texas 78217

(Address of principal executive offices, including zip code)

(210) 698-5334

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

| ☐ | Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| --- | --- |
| ☐ | Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

| Title
of each class | Trading
Symbols | Name
of each exchange on which registered |
| --- | --- | --- |
| Common
Stock, par value $0.007 per share | BIAF | The
Nasdaq Stock Market LLC (Nasdaq
Capital Market) |
| Warrants to purchase Common
Stock | BIAFW | The
Nasdaq Stock Market LLC (Nasdaq
Capital Market) |

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 8.01. Other Events.

On September 9, 2025, bioAffinity Technologies, Inc., a Delaware corporation, (the “Company”) issued a press release announcing the release of a new case study in which CyPath® Lung identified cancer in a patient with an incidental finding of ground glass nodules.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Press Release issued by bioAffinity Technologies, Inc., dated September 9, 2025
104	Cover Page Interactive
Data File (embedded within the XBRL document)

Field: Page; Sequence: 2; Options: NewSection; Value: 2

• 2 -

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 9, 2025
By:	/s/ Maria
Zannes
Name:	Maria Zannes
Title:	President and Chief
Executive Officer

Field: Page; Sequence: 3; Options: Last

• 3 -

Field: /Page

Field: Set; Name: xdx; ID: xdx_08B_extensions eJx1kcFuwjAMhp+Ad7CqHRFLO23TemMVQ9NgqgCxXU0xI6KNKydl8Eh7y6UpCA5bZCly/H/+bSWK+tGYX3RJAp/PswksqKpLdAQz2pCQKcgrste3FPw9oy9tnaBxIT2DGXuGPPMwiFf+PSj32tI6BfV06yO5h1ildwqG06jX1jM2G70m4zSWgGYNuXAtmhzKseuwwAMbro7BaUliNZsU4oHqyj+QqDiBd97jN8vOwmSSRb1+OL1oLNzUXjU6ODItCaOSKm9nO/oSYZqisY6r9AOl3c0uOG+k2KIlv1nFZu642E2pWpF4caySJFbD0xxnBhxDfaKgwyBwf/hcdc1Rllg2pAZKPeYk8y0K/WN13bUPNQrsWxRuAgy1/wnb4mfHX7EFjrs=